Mineralys Therapeutics, Inc. · NASDAQ:MLYS

Mineralys Therapeutics — Investor Presentation (October 2026)

21 slides from Mineralys Therapeutics's investor presentation, October 2026

  1. Slide 1: Targeting Aldosterone in the Treatment of Cardiorenal Diseases

    Targeting Aldosterone in the Treatment of Cardiorenal Diseases October 2026 © 2026 Mineralys Therapeutics, Inc. All Rights Reserved. © 2026 Mineralys Therapeutics, Inc.

  2. Slide 2: Forward-Looking Statements and Market Data

    Forward-Looking Statements and Market Data Mineralys Therapeutics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and in

  3. Slide 3: Targeting Aldosterone in the Treatment of Hypertension and Cardiorenal Diseases

    • Dysregulated aldosterone is the driver in 30% of uncontrolled and resistant hypertension (u/rHTN) Targeting • Lorundrostat demonstrated meaningful 24-hour BP Aldosterone reduction and safety of once-daily dosing in participants with u/rHTN in the Treatment of • Demonstrated benefit in HTN particip

  4. Slide 4: Dysregulated Aldosterone In Hypertension and Related Comorbidities

    Dysregulated Aldosterone In Hypertension and Related Comorbidities © 2026 Mineralys Therapeutics, Inc. All Rights Reserved. © 2026 Mineralys Therapeutics, Inc.

  5. Slide 5: Abnormally Elevated Aldosterone Impacts Multiple Biological Pathways and is a Key Driver in Cardiorenal Diseases

    Abnormally Elevated Aldosterone Impacts Multiple Biological Pathways and is a Key Driver in Cardiorenal Diseases Genomic Effects Non-Genomic Effects (MINERALOCORTICOID RECEPTOR) Aldosterone (GPR30 RECEPTOR) Na+ and water retention Drives endothelial and renal tubular drives blood volume and oxidativ

  6. Slide 6: Lorundrostat Potential Benefit Across Aldosterone Spectrum

    Lorundrostat Potential OBESE UNCONTROLLED HYPERTENSION HTN in the U.S. OSA in the U.S. Benefit Across Nighttime BP 30% prevalence of dysregulated aldo in Spectrum TREATMENT- link to CV risk OBSTRUCTIVE SLEEP APNEA RESISTANT u/rHTN HYPERTENSION 70-80% prevalence of CRMS1-5 of rHTN in OSA Visceral adi

  7. Slide 7: Uncontrolled and Resistant Hypertension Is the Leading Global Modifiable Risk Factor for Cardiovascular Death

    Uncontrolled and Resistant Hypertension Is the Leading Global Modifiable Risk Factor for Cardiovascular Death Top 8 Global Modifiable Risk Factors Risk Reduction per 10mmHg for CV Deaths in 20211 Reduction in Systolic BP 2 0% 10.8 Kidney dysfunction All Cause CHD Major CV Stroke HF Mortality Events

  8. Slide 8: The Unmet Need in u/rHTN is Largely Driven by Aldosterone

    20-40% of hypertension patients have uncontrolled or resistant HTN • Half of the treated HTN patients in the U.S. fail to achieve goal1 • Prevalence of apparent rHTN demonstrated to be ~20%2 • In optimized background treatment trials, 30-40% of participants fail to The Unmet Need achieve goal3 in u/

  9. Slide 9: Lorundrostat Clinical Efficacy and Safety

    Lorundrostat Clinical Efficacy and Safety © 2026 Mineralys Therapeutics, Inc. All Rights Reserved. © 2026 Mineralys Therapeutics, Inc.

  10. Slide 10: Clinically Meaningful Efficacy across Participant Subgroups

    Clinically Meaningful Efficacy across Participant Subgroups Reductions in SBP of this magnitude have been linked to significant reduction in overall cardiovascular risk1 u/r/HTN participants on prescribed regimen Change in 24hr ABPM in mmHg Change in AOBP in mmHg Change in AOBP in mmHg of 2-5 AHTs (

  11. Slide 11: Favorable Safety and Tolerability Profile across Patient and Prescriber Types

    Favorable Safety and Tolerability Profile across Patient and Prescriber Types Very low rates of serious adverse events and treatment discontinuations (“Real World”) (“Specialist”) (“Compromised Kidney Function”) (“Obstructive Sleep Apnea”) Lorundrostat: N=538 Lorundrostat: N=94 Lorundrostat: N=58 Lo

  12. Slide 12: Lorundrostat Potassium Profile Similar to ACE Inhibitor and ARBs – Predictable and Modest

    Lorundrostat Potassium Profile Similar to ACE Inhibitor and ARBs – Predictable and Modest Hyperkalemia (K+ > 6.0) at • Lorundrostat potassium levels are very mild and Study Visit and Repeat Test (%) consistent with observed levels of ACE inhibitors and ARBs today* ARBs 2.8 • Potassium levels were mi

  13. Slide 13: Lorundrostat Development Program with Positive Pivotal Data and Market Expansion Proof-of-Concept Trials

    Lorundrostat Development Program with Positive Pivotal Data and Market Expansion Proof-of-Concept Trials Trial Safety Proof of Concept Pivotal Status u/rHTN Existing background AHT Completed u/rHTN Optimized background AHT Completed Hypertension u/rHTN Existing background AHT Completed Open-Label Ex

  14. Slide 14: Significant Commercial Opportunity in CRMS

    Significant Commercial Opportunity in CRMS © 2026 Mineralys Therapeutics, Inc. All Rights Reserved. © 2026 Mineralys Therapeutics, Inc.

  15. Slide 15: Large Total Addressable Market: 20M People in U.S. with Uncontrolled or Resistant Hypertension

    Large Total Addressable Market: 20M People in U.S. with Uncontrolled or Resistant Hypertension and Related Comorbidities ~120M PATIENT POPULATION HTN PATIENTS IN THE U.S. BREAKDOWN IN THE U.S uHTN (1 AHT) Addressable ~10M Market HTN under UNTREATED TREATED control uHTN (2 AHT) 20M u/rHTN 60M 60M ~30

  16. Slide 16: 8.8 Million u/rHTN Patients per Year Try New Treatments - an Opportunity for Lorundrostat

    8.8 Million u/rHTN Patients per Year Try New Treatments - an Opportunity for Lorundrostat More than half of new-to-line patients each year would be eligible for lorundrostat 3L+ treatment Eligible New Patient New-to-Line vs Existing New-to-Line Patient Line Pool per year Patient Distribution of Ther

  17. Slide 17: Majority of PCPs, Cardiologists and Nephrologists Likely to Prescribe Lorundrostat

    Per Market Research, the Majority of PCPs, Cardiologists and Nephrologists Are Likely to Prescribe Lorundrostat Based on Efficacy and Safety Profile Likelihood to prescribe Likelihood to prescribe lorundrostat Those surveyed preferred lorundrostat for u/rHTN for u/rHTN with CKD lorundrostat vs baxdr

  18. Slide 18: Launch Plan Builds Upon u/rHTN Opportunity and Addresses Additional Areas of Unmet Clinical Need

    Launch Plan Builds Upon u/rHTN Opportunity and Addresses Additional Areas of Unmet Clinical Need Inclusion of ASI in AHA hypertension treatment guidelines Potential best-in-class SBP reductions & safety in u/rHTN informs general prescribing (Launch-HTN) Confirmed u/rHTN Advance-HTN: Only ASI studied

  19. Slide 19: Financial Summary

    Financial Summary Research Analyst Coverage BofA Securities Jason Gerberry Evercore ISI Umer Raffat/Mike DiFiore Goldman Sachs Richard Law Nasdaq MLYS Stifel Annabel Samimy Guggenheim Securities Seamus Fernandez June 30, 2026 Cash Balance* $661M Wells Fargo Securities Mohit Bansal Shares of common s

  20. Slide 20: Mineralys Leadership Team

    Mineralys Leadership Team Agile and experienced in developing novel, leading therapies Jon Congleton Adam Levy Eric Warren Chief Executive Officer Chief Financial Officer Chief Commercial Officer 30+ years of experience: Marion, HMR, 15+ years of banking experience: Merrill 30+ years of experience:

  21. Slide 21: © 2026 Mineralys Therapeutics, Inc. All Rights Reserved.

    © 2026 Mineralys Therapeutics, Inc. All Rights Reserved. © 2026 Mineralys Therapeutics, Inc.

Mineralys Therapeutics — Investor Presentation (October 2026) on 6ix